+++Meanwhile, Insmed has not submitted for approval in Europe for primary IGFD (non-severe). They either prefer to go after alternate indications with much bigger markets than 30,000 patients, or, they are just a bit behind getting their EMEA (european fda equivalent body) submission in.+++
Baxter is quite close-mouthed about this. His response to my questions about it was "We have not commented on the EMEA filing yet."
I was trying to find out if they were waiting for a European partner for the filing, as has been speculated.
Read what you will in it.
Regards,
bob
Market Data 
Markets 
AI
